CORMEDIX INC. APIC, Share-based Payment Arrangement, Other, Increase for Cost Recognition
CORMEDIX INC. (CRMD) reported APIC, Share-based Payment Arrangement, Other, Increase for Cost Recognition of $4.07 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-30.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition · last filed 2023-03-30
- CORMEDIX INC. apic, share-based payment arrangement, other, increase for cost recognition for the quarter ending 2022-12-31 was $874.05K, a 30.26% decline year-over-year.
- CORMEDIX INC. apic, share-based payment arrangement, other, increase for cost recognition for the quarter ending 2022-09-30 was $983.52K, a 6.12% decline year-over-year.
- CORMEDIX INC. apic, share-based payment arrangement, other, increase for cost recognition for the quarter ending 2022-06-30 was $1.07M, a 6.29% increase year-over-year.
- CORMEDIX INC. apic, share-based payment arrangement, other, increase for cost recognition for the quarter ending 2022-03-31 was $1.14M, a 34.26% decline year-over-year.
- CORMEDIX INC. apic, share-based payment arrangement, other, increase for cost recognition for fiscal 2022 was $4.07M, a 19.30% decline from fiscal 2021.
- CORMEDIX INC. apic, share-based payment arrangement, other, increase for cost recognition for fiscal 2021 was $5.04M, a 101.72% increase from fiscal 2020.
- CORMEDIX INC. apic, share-based payment arrangement, other, increase for cost recognition for fiscal 2020 was $2.50M, a 2.47% increase from fiscal 2019.
- CORMEDIX INC. apic, share-based payment arrangement, other, increase for cost recognition for fiscal 2019 was $2.44M.
| Period end | APIC, Share-based Payment Arrangement, Other, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Other, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Other, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Other, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2022-12-31 | $874.05K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $1.86M derived: sum of 2 quarters · filed 2023-03-30 | $2.93M derived: sum of 3 quarters · filed 2023-03-30 | $4.07M 10-K · filed 2023-03-30 |
| 2022-09-30 | $983.52K 10-Q · filed 2022-11-10 | $2.06M derived: sum of 2 quarters · filed 2022-11-10 | $3.20M 10-Q · filed 2022-11-10 | $4.45M derived: sum of 4 quarters · filed 2023-03-30 |
| 2022-06-30 | $1.07M 10-Q · filed 2022-08-11 | $2.21M 10-Q · filed 2022-08-11 | $3.47M derived: sum of 3 quarters · filed 2023-03-30 | $4.51M derived: sum of 4 quarters · filed 2023-03-30 |
| 2022-03-31 | $1.14M 10-Q · filed 2022-05-12 | $2.39M derived: sum of 2 quarters · filed 2023-03-30 | $3.44M derived: sum of 3 quarters · filed 2023-03-30 | $4.45M derived: sum of 4 quarters · filed 2023-03-30 |
| 2021-12-31 | $1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $2.30M derived: sum of 2 quarters · filed 2023-03-30 | $3.31M derived: sum of 3 quarters · filed 2023-03-30 | $5.04M 10-K · filed 2023-03-30 |
| 2021-09-30 | $1.05M 10-Q · filed 2022-11-10 | $2.06M derived: sum of 2 quarters · filed 2022-11-10 | $3.79M 10-Q · filed 2022-11-10 | $4.31M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $1.01M 10-Q · filed 2022-08-11 | $2.74M 10-Q · filed 2022-08-11 | $3.26M derived: sum of 3 quarters · filed 2022-08-11 | $3.87M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $1.73M 10-Q · filed 2022-05-12 | $2.25M derived: sum of 2 quarters · filed 2022-05-12 | $2.86M derived: sum of 3 quarters · filed 2022-05-12 | $3.55M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $516.18K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $1.13M derived: sum of 2 quarters · filed 2022-03-29 | $1.82M derived: sum of 3 quarters · filed 2022-03-29 | $2.50M 10-K · filed 2022-03-29 |
| 2020-09-30 | $611.44K 10-Q · filed 2020-11-05 | $1.31M derived: sum of 2 quarters · filed 2020-11-05 | $1.98M 10-Q · filed 2020-11-05 | $2.44M derived: sum of 4 quarters · filed 2021-05-13 |
| 2020-06-30 | $695.59K 10-Q · filed 2020-08-10 | $1.37M 10-Q · filed 2020-08-10 | $1.83M derived: sum of 3 quarters · filed 2021-05-13 | $2.40M derived: sum of 4 quarters · filed 2021-05-13 |
| 2020-03-31 | $676.61K 10-Q · filed 2021-05-13 | $1.13M derived: sum of 2 quarters · filed 2021-05-13 | $1.70M derived: sum of 3 quarters · filed 2021-05-13 | $2.31M derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $453.34K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | $1.02M derived: sum of 2 quarters · filed 2021-03-30 | $1.63M derived: sum of 3 quarters · filed 2021-03-30 | $2.44M 10-K · filed 2021-03-30 |
| 2019-09-30 | $570.61K 10-Q · filed 2020-11-05 | $1.18M derived: sum of 2 quarters · filed 2020-11-05 | $1.99M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $606.33K 10-Q · filed 2020-08-10 | $1.42M 10-Q · filed 2020-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |